News and Press Releases
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
ACES-EMB is the first randomized-controlled trial to compare dd-cfDNA surveillance to routine biopsy in organ transplantation, highlighting the benefits of Prospera in organ rejection 28 January 2026 -- Texas, US...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2026
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
Issued and pending claims expected to protect ALTO-207 into the mid-2040s 14 January 2026 -- California, US -- Alto Neuroscience, Inc, a clinical-stage biopharmaceutical company focused on the development of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2026
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
New AI-derived model integrates longitudinal ctDNA and clinical data with digital pathology and tumor sequencing data, to refine recurrence risk assessment and outcomes prediction 13 January 2026 -- Texas, US...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 13, 2026
ConcertAI and Foundation Medicine Integrate Genomic and Clinical Data to Transform Translational Research and Efficient Drug Development
ConcertAI now offers industry’s most comprehensive clinically-linked dataset to life science organizations Dataset encompasses ConcertAI’s full network of industry partners, representing nearly half a million patients Applications span entire drug...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: January 12, 2026
Groundbreaking myalgic encephalomyelitis study identifies over 250 core genes, shared biology with long COVID, and dozens of drug repurposing opportunities
The study reinforces that ME is a complex multisystemic condition with a clear genetic basis and lays the foundation for future clinical trials that could be faster to recruit and...
Category: BioManufacturing, Clinical Trials, Other, Pharmaceutical
Posted: December 4, 2025
Integrated DNA Technologies and Beckman Coulter Life Sciences Partner to Advance Cancer Research Through Automated NGS Workflows
Collaboration aims to equip users with complete NGS solution from sample to answer 12 November 2025 -- Colorado and Indiana, US -- Danaher companies Integrated DNA Technologies (IDT), a global leader in...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: November 12, 2025
PlaqueTec announces positive early research findings from interim analysis in BIOPATTERN trial
Pre-specified interim analysis reveals differences in protein concentration between systemic blood and blood from diseased coronary arteries Safety and functionality data for the updated Liquid Biopsy System supports continuation of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025
Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers
23 April 2025 -- Ingelheim, Germany and Amsterdam, the Netherlands -- Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025
Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round
Led by Ventura Capital and joined by other investors including Aviva Ventures, the Gates Foundation and Horizons Ventures Funding will be used to accelerate commercialization and further clinical trials of...
Category: Drug Discovery
Posted: January 17, 2025
Owlstone Ltd, 127 Cambridge Science Park, Milton Road, Cambridge, CB4 0GD, UK
QurAlis Invited to Present at 43rd Annual J.P. Morgan Healthcare Conference
7 January 2025 -- Massaschusetts, US -- QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of amyotrophic...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 7, 2025
Closed Loop Medicine demonstrates application of digital platform for remote blood pressure and medication monitoring
Study published in JMIR validates the feasibility, use and safety of a digital platform for remote, routine monitoring of blood pressure and medication in hypertension patients Findings support the use...
Category: Biotechnology, Other, Pharmaceutical
Posted: December 17, 2024
Babraham Research Campus Cambridge CB22 3AT United Kingdom
Owkin announces partnership with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer
2 October 2024 -- Paris, France -- Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 2, 2024
Closed Loop Medicine appoints Luba Greenwood as Chair of the Board of Directors
Appointment of notable investor and executive in healthcare and tech to support leadership team in preparation for commercial milestones 11 Sep 2024 -- London, UK -- Closed Loop Medicine Ltd.,...
Category: Biotechnology, Other, Pharmaceutical
Posted: September 11, 2024
Babraham Research Campus Cambridge CB22 3AT United Kingdom
Closed Loop Medicine appoints Paul Johnson as Non-Executive Director
Appointment of digital healthcare leader to Board to support the company as it enters next phase of commercial development Co-founder and former CEO of Lemonaid Health, a leading innovator in...
Category: Biotechnology, Pharmaceutical
Posted: May 22, 2024
Babraham Research Campus Cambridge CB22 3AT United Kingdom
Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic
Proof-of-concept study to investigate personalised dose management of first-line anti-hypertensive in improving blood pressure control remotely Key milestone in co-development partnership to combine leading medicine brands with dose optimisation technology...
Category: Biotechnology, Clinical Trials
Posted: May 16, 2024
Babraham Research Campus Cambridge CB22 3AT United Kingdom
